Call to Action for Cancer Care Improvement Act

Representatives Lois Capps and Charles Boustany have introduced the Comprehensive Cancer Care Improvement Act (H.R. 1844), which would improve care for lymphoma patients by encouraging comprehensive cancer care planning from the point of diagnosis through primary treatment and into survivorship. Remember: legislators will not support the bill unless they hear from you!

The Lymphoma Research Foundation (LRF) encourages every member of the lymphoma community to contact their U.S. Representative and urge them to co-sponsor this important legislation. Call your Representative, and using the talking points below, tell them we need their support! You may reach your Representative via the Capitol Switchboard at (202) 224-3121. Ask the operator to transfer you to your Representative's office.

Talking Points For Phone Calls To U.S. Representatives

  • • Tell staff you are calling to urge your Representative to co-sponsor the Comprehensive Cancer Care Improvement Act, H.R. 1844.
  • • The bill would encourage heath care providers to: 1) develop a written cancer care plan for patients and 2) review the details of the plan with their patients before treatment begins and then again at the conclusion of their treatment.
  • • The bill would also allow Medicare to reimburse physicians for the time required to develop and communicate these plans to patients, an important consideration as the majority of U.S cancer patients are beneficiaries of that program.
  • • Add any personal connection to lymphoma that you wish to share and/ or why this legislation would help you, your family, or someone you know whose life has been affected by lymphoma.
  • • Ask your Representative to co-sponsor the Comprehensive Cancer Care Improvement Act by contacting the offices of Representatives Lois Capps or Charles Boustany.
  • • Remember to leave your name and address, so that your Representative can follow-up and inform you whether he or she co-sponsored the bill.
Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap